Loading...
Market
Will subcutaneous Nivolumab be in NCCN lung cancer guidelines by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
National Comprehensive Cancer Network (NCCN) guidelines publications
Story
FDA Approves Subcutaneous Nivolumab by Bristol Myers Squibb for Advanced or Metastatic Solid Tumors
Dec 27, 2024, 04:10 PM
The U.S. Food and Drug Administration (FDA) has approved a subcutaneous formulation of Nivolumab, also known as Opdivo, for use in patients with advanced or metastatic solid tumors. This approval, announced on December 27, 2024, allows for an injectable version of the drug, which is manufactured by Bristol Myers Squibb. The approval is expected to enhance treatment options for patients suffering from various types of cancer, including lung and gastrointestinal cancers, as well as breast cancer, where recent studies have indicated the drug's efficacy in combination with other therapies. The FDA's decision follows a series of discussions and presentations at recent oncology conferences, highlighting the importance of personalized cancer care and the role of biomarkers in treatment decisions.
View original story
Similar markets
Yes • 50%
No • 50%
Tagrisso • 25%
RYBREVANT and LAZCLUZE • 25%
Keytruda • 25%
Other • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca/Daiichi Sankyo • 25%
Yes • 50%
No • 50%
Accelerated Approval • 25%
Full Approval • 25%
No Approval • 25%
Conditional Approval • 25%